Results 161 to 170 of about 6,119 (209)

Spravato (Esketamine)

Asian Journal of Nursing Education and Research, 2023
Depression is more than feeling a little sad or "blue" for a few days. Antidepressant medications are used in the treatment of clinical depression, usually alongside other forms of therapy such as psychological or behavioral therapy. Spravato is a medicine used to treat adults with major depression that is resistant to treatment.
Nirosha V., Gayathri V.
openaire   +1 more source

Esketamine

Reactions Weekly, 2022
  +4 more sources

Esketamine for treatment-resistant depression

Drug and Therapeutics Bulletin, 2020
Generic name: Esketamine hydrochloride Brand name: Spravato Formulation: 28mg in 0.2ml nasal spray solution Market Authorisation holder: Janssen-Cilag International NV Indication: Treatment resistant
openaire   +2 more sources

NICE reconsiders esketamine for depression

BMJ, 2020
The National Institute for Health and Care Excellence (NICE) has launched a second consultation on the use of esketamine for treatment resistant depression, after feedback showed that it could benefit some patients. Guidance published in January 2020 did not recommend esketamine for treatment resistant depression and said that the drug should not be ...
openaire   +2 more sources

Esketamine for Treatment-Resistant Depression

JAMA Psychiatry
To the Editor Janik et al reported a positive trial of esketamine monotherapy for treatment-resistant depression. However, the lead-in design and functional unblinding could have biased treatment estimates. The 4-week double-blind phase was preceded by a lead-in phase of up to 7 weeks, during which time antidepressant medication was discontinued ...
Cristea I. A., Plöderl M., Naudet F.
openaire   +4 more sources

Esketamine for Postpartum Suicidality

Biological Psychiatry, 2021
Catarina, Machado, Acioly L T, Lacerda, Rodrigo A, Bressan, Cristiano, Noto   +3 more
openaire   +2 more sources

Ketamin und Esketamin

Nervenheilkunde
ZUSAMMENFASSUNGKetamin blickt bereits auf eine längere Geschichte der Anwendung in der Psychiatrie zurück. Insbesondere ist es in den letzten 2 Dekaden zur Behandlung von therapieresistenten Depressionen erforscht und eingesetzt worden und ist mit dem Enantiomer Esketamin in Deutschland für diese Indikation zugelassen.
Cornelius Schüle, Gabi Koller, Uwe Herwig   +2 more
openaire   +1 more source

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Journal of Affective Disorders, 2021
Anees Bahji
exaly  

Esketamine

2023
openaire   +1 more source

Esketamine

Reactions Weekly, 2019
openaire   +2 more sources